Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Epidemiology
Published in: European Journal of Epidemiology 7/2018

01-07-2018 | PSYCHIATRIC EPIDEMIOLOGY

A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013

Authors: Phillip L. Marotta, Charlotte A. McCullagh

Published in: European Journal of Epidemiology | Issue 7/2018

Login to get access

Abstract

Data at the individual-level provide evidence that opioid substitution treatment (OST) programs protect against mortality for opioid dependent populations. Prior research has not examined the merits of national implementation of opioid substitution programs for reducing mortality at the country-level. This study elucidates longitudinal associations between country-level implementation of opioid substitution treatment programs on mortality rates of drug related deaths (DRD) from 1995 to 2013 in 30 European nations. Cases of DRD were measured using National Definitions for each country from official sources of data. Preliminary analysis of dispersion of cases of DRD using means and variances justified use of the negative binomial regression model with a population offset. Year and country-level fixed effects negative binomial regression models investigated the association between years of implementation of methadone maintenance therapy (MMT), OST in prison, and high dose buprenorphine treatment (HDBT) implementation and mortality rates from drug related deaths after adjusting for unemployment rates, heroin seizures and per capita expenditures on health. Beta coefficients were converted to Incidence Rate Ratios (IRR) and standard errors bootstrapped using non-parametric methods to adjust for bias (SDbs). The mean mortality rate of DRD was 1.81 from 1995 to 2013. In adjusted models, each additional year of MMT (IRR = .61, SD = .04, p < .001; SDbs = .08, p < .001), prison OST (IRR = .90, SD = .01, p < .001; SDbs = .02, p < .001), and HDBT (IRR = .09, SD = .02, p < .001; SDbs = .02, p < .01) was significantly associated with lower rates of DRDs after adjusting for country and year fixed effects. Implementation of OST programs in the general population and in prison settings may have protected against mortality from drug use at the country-level in Europe from 1995 to 2013.
Literature
1.
Frisher M, Baldacchino A, Crome I, Bloor R. Preventing opioid overdoses in Europe: A critical assessment of known risk factors and preventative measures. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, EMCDDA, Technical paper; 2012.
2.
3.
4.
5.
Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26(7):626–31.PubMedCrossRef
6.
Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1):73–7.PubMedCrossRef
7.
Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1):151–7.PubMedCrossRef
8.
Degenhardt L, Larney S, Randall D, Burns L, Hall W. Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction. 2014;109(1):90–9.PubMedCrossRef
9.
Hulse GK, English DR, Milne E, Holman CDJ. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94(2):221–9.PubMedCrossRef
10.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171.PubMed
11.
Espelt A, Barrio G, Álamo-Junquera D, Bravo MJ, Sarasa-Renedo A, Vallejo F, Molist G, Brugal MT. Lethality of opioid overdose in a community cohort of young heroin users. Eur Addict Res. 2015;21(6):300–6.PubMedCrossRef
12.
Morgan O, Vicente J, Griffiths P, Hickman M. Trends in overdose deaths from drug misuse in Europe: what do the data tell us? Addiction. 2008;103(5):699–700.PubMedCrossRef
13.
Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18(5):228–45.PubMedCrossRef
14.
Kraus M, Lintzeris N, Maier C, Savage S. Recommendations for the prevention, detection, treatment and management of prescription opioid analgesic dependence: outcomes from the opioid analgesic dependence education nexus (open) meeting. Int J Ment Health Addict. 2016;14(3):313–21.PubMedCrossRef
15.
Van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev. 2015;8(1):3–14.PubMedCrossRef
16.
Kraus M, Lintzeris N, Maier C, Savage S. Recommendations for the prevention, detection, treatment and management of prescription opioid analgesic dependence: outcomes from the Opioid Analgesic Dependence Education Nexus (OPEN) meeting. Int J Ment Health Addict. 2016;14(3):313–21.
17.
Glaeske G. Psychotrope und andere Arzneimittel mit Missbrauchs- und Abhangikeitspotential (Psychotrope and other pharmaceuticals with abuse or dependence potential); in Duetsch Hauptstelle gegen die Suchtgefahren: Jahrbuch Sucht. Geesthach Neuland; 2005. p. 52–68.
18.
19.
Kimber J, Palmateer N, Hutchinson SJ, Hickman M, Goldberg DJ, Rhodes T. Harm reduction among injecting drug users-evidence of effectiveness. In: Harm reduction: evidence, impacts and challenges EMCDDA, Lisbon, April 2010. European Monitoring Centre for Drugs and Drug Addiction; 2010 p. 115–163.
20.
Stevens A. Drugs, crime and public health: the political economy of drug policy. London: Routledge; 2010.
21.
Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.PubMedPubMedCentralCrossRef
22.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, De La Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100(7):981–9.PubMedCrossRef
23.
Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177–96.PubMedCrossRef
24.
Davstad I, Stenbacka M, Leifman A, Romelsjö A. An 18-year follow-up of patients admitted to methadone treatment for the first time. J Addict Dis. 2009;28(1):39–52.PubMedCrossRef
25.
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1):9–15.PubMedCrossRef
26.
Fei JTB, Yee A, Habil MHB, Danaee M. Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. J Subst Abuse Treat. 2016;69:50–6.CrossRef
27.
Langendam MW, Van Brussel GH, Coutinho RA, Van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774.PubMedPubMedCentralCrossRef
28.
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37.PubMedCrossRef
29.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3(3):CD002209.
30.
Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–8.PubMedCrossRef
31.
Peles E, Schreiber S, Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2010;107(2):141–8.PubMedCrossRef
32.
Torrens M, Fonseca F, Castillo C, Domingo-Salvany A. Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull World Health Organ. 2013;91(2):136–41.PubMedPubMedCentralCrossRef
33.
Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, Wood E. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.PubMedCrossRef
34.
Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285(1):45.PubMedCrossRef
35.
Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96(5):683–90.PubMedCrossRef
36.
Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.PubMedCrossRef
37.
Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533–42.PubMedCrossRef
38.
Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol. 2004;24(5):479–87.PubMedCrossRef
39.
Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol. 2006;26(6):657–60.PubMedCrossRef
40.
Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358–64.PubMedCrossRef
41.
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–8.PubMedCrossRef
42.
Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna‐Taglianti F, Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102(12):1954–9.PubMedCrossRef
43.
Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257–60.PubMedCrossRef
44.
Butler T, Kariminia A, Levy M, Murphy M. The self-reported health status of prisoners in New South Wales. Aust N Z J Public Health. 2004;28(4):344–50.PubMedCrossRef
45.
Nordt C, Stohler R. Combined effects of law enforcement and substitution treatment on heroin mortality. Drug Alcohol Rev. 2010;29(5):540–5.PubMedCrossRef
46.
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.PubMedCrossRef
47.
Favrod-Coune T, Baroudi M, Casillas A, Rieder JP, Gétaz L, Barro J, Gaspoz JM, Broers B, Wolff H. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland. Swiss Med Wkly. 2013;143:w13898.PubMed
48.
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urb Health. 2010;87(4):592–602.CrossRef
49.
Strang J, Bird SM, Parmar MK. Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial. J Urb Health. 2013;90(5):983–96.CrossRef
50.
Dolan KA, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev. 1998;17(2):153–8.PubMedCrossRef
51.
Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103(8):1333–42.PubMedPubMedCentralCrossRef
52.
Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM. Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. Drug Alcohol Depend. 2006;83(2):122–9.PubMedCrossRef
53.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277–85.PubMedPubMedCentralCrossRef
54.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners 3-month postrelease outcomes. Crim Justice Behav. 2008;35(1):34–47.PubMedPubMedCentralCrossRef
55.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2):220–7.PubMedPubMedCentralCrossRef
56.
Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum A. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1):222–30.PubMedCrossRef
57.
Bevan G. Problem drug use the public health imperative: what some of the literature says. Subst Abuse Treat Prev Policy. 2009;4(1):1.CrossRef
58.
Bazazi AR, Zelenev A, Fu JJ, Yee I, Kamarulzaman A, Altice FL. High prevalence of non-fatal overdose among people who inject drugs in Malaysia: correlates of overdose and implications for overdose prevention from a cross-sectional study. Int J Drug Policy. 2015;26(7):675–81.PubMedCrossRef
59.
Fischer B, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noël L, Rehm J, Tyndall M, Wild C, Mun P, Haydon E. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. Can Med Assoc J. 2004;171(3):235–9.CrossRef
60.
Green TC, Grau LE, Blinnikova KN, Torban M, Krupitsky E, Ilyuk R, Kozlov A, Heimer R. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy. 2009;20(3):270–6.PubMedCrossRef
61.
Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.PubMedCrossRef
62.
Milloy MJ, Fairbairn N, Hayashi K, Suwannawong P, Kaplan K, Wood E, Kerr T. Overdose experiences among injection drug users in Bangkok, Thailand. Harm Reduct J. 2010;7(1):9.PubMedPubMedCentralCrossRef
63.
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, Hankins CA. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.PubMedCrossRef
64.
Bokhari FA, Gai Y, Gottret P. Government health expenditures and health outcomes. Health Econ. 2007;16(3):257–73.PubMedCrossRef
65.
Bradley EH, Elkins BR, Herrin J, Elbel B. Health and social services expenditures: associations with health outcomes. Qual Saf Health Care. 2011;20:826–31.
66.
Nixon J, Ulmann P. The relationship between health care expenditure and health outcomes. Eur J Health Econ. 2006;7(1):7–18.PubMedCrossRef
67.
Marotta PL, McCullagh CA. A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011. Int J Drug Policy. 2016;32:3–10.PubMedPubMedCentralCrossRef
68.
69.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
70.
World Bank Group, editor. World development indicators 2012. Washington, DC: World Bank Publications; 2012.
71.
Kreft IG, Kreft I, de Leeuw J. Introducing multilevel modeling. Thousand Oaks: Sage; 1998.CrossRef
72.
Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. College Station: STATA Press; 2008.
73.
74.
Hilbe JM. Negative binomial regression. Cambridge: Cambridge University Press; 2011.CrossRef
75.
Piegorsch WW. Maximum likelihood estimation for the negative binomial dispersion parameter. Biometrics. 1990;46:863–7.PubMedCrossRef
76.
Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull. 1995;118(3):392.PubMedCrossRef
77.
Kim MS, Sun Y. Bootstrap and k-step bootstrap bias corrections for the fixed effects estimator in nonlinear panel data models. Econom Theory. 2016;32(6):1523–68.CrossRef
78.
Cameron AC, Trivedi PK. Microeconometrics using stata, vol. 2. College Station: Stata press; 2010.
79.
Greenfield VA, Paoli L. If supply-oriented drug policy is broken, can harm reduction help fix it? Melding disciplines and methods to advance international drug-control policy. Int J Drug Policy. 2012;23(1):6–15.PubMedCrossRef
80.
Weatherburn D, Jones C, Freeman K, Makkai T. Supply control and harm reduction: lessons from the Australian heroin ‘drought’. Addiction. 2003;98(1):83–91.PubMedCrossRef
81.
Wood E, Tyndall MW, Spittal PM, Li K, Anis AH, Hogg RS, Montaner JS, O’shaughnessy MV, Schechter MT. Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. Can Med Assoc J. 2003;168(2):165–9.
82.
Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228–48.PubMedPubMedCentralCrossRef
83.
Cerdá M, Ransome Y, Keyes KM, Koenen KC, Tardiff K, Vlahov D, Galea S. Revisiting the role of the urban environment in substance use: the case of analgesic overdose fatalities. Am J Public Health. 2013;103(12):2252–60.PubMedPubMedCentralCrossRef
84.
Nandi A, Galea S, Ahern J, Bucciarelli A, Vlahov D, Tardiff K. What explains the association between neighborhood-level income inequality and the risk of fatal overdose in New York City? Soc Sci Med. 2006;63(3):662–74.PubMedCrossRef
85.
Beletsky L, Grau LE, White E, Bowman S, Heimer R. The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs. Addiction. 2011;106(2):357–65.PubMedCrossRef
86.
Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health. 2005;95(2):233–6.PubMedPubMedCentralCrossRef
87.
Gyarmathy VA, Neaigus A. Marginalized and socially integrated groups of IDUs in Hungary: potential bridges of HIV infection. J Urb Health. 2005;82(4):iv101–12.
88.
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.PubMedCrossRef
89.
Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44(2):241–7.PubMedCrossRef
90.
Davis CS, Carr D, Southwell JK, Beletsky L. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health. 2015;105(8):1530–7.PubMedPubMedCentralCrossRef
91.
Strathdee SA, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. 2015;26:S27–32.PubMedCrossRef
Metadata
Title
A cross-national analysis of the association between years of implementation of opioid substitution treatments and drug-related deaths in Europe from 1995 to 2013
Authors
Phillip L. Marotta
Charlotte A. McCullagh
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 7/2018
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-017-0342-z

Other articles of this Issue 7/2018

European Journal of Epidemiology 7/2018 Go to the issue

NEURO-EPIDEMIOLOGY

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease

COMMENTARY

Broadening the scope of epidemiologic dementia research

NEURO-EPIDEMIOLOGY

External validation of four dementia prediction models for use in the general community-dwelling population: a comparative analysis from the Rotterdam Study

LETTER TO THE EDITOR

How accurately is euthanasia reported on death certificates in a country with legal euthanasia: a population-based study

META-ANALYSIS

Age-specific ALS incidence: a dose–response meta-analysis

NEURO-EPIDEMIOLOGY

The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?